# US 11,439,631 B2 · Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,631 B2
- Document ID: US11439631B2
- Status: Granted
- Kind: B2
- Application number: 16/644,899
- Filed: 2018-03-06
- Published: 2020-06-18
- Granted: 2022-09-13
- Earliest claimed: 2017-09-07
- Assignees: "Chemimmune Therapeutics" Limited Liability Company
- Applicants: “Chemimmune Therapeutics” Limited Liability Company
- Inventors: Vladimir Evgenievich Nebolsin; Anastasia Vladimirovna Rydlovskaya
- Web page: https://patentgrep.com/patent/US11439631B2

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to medicine and concerns the treatment of diseases related to the aberrant activity of fractalkine and monocyte chemoattractant proteins 1-4 (CCL2, CCL7, CCL8, CCL13), preferably the treatment of pain, fever, pneumonia, bronchitis, bronchiolitis, alveolitis, rheumatoid arthritis, psoriasis and other diseases, using the compound 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione or a pharmaceutically acceptable salt or solvate thereof The present invention also relates to pharmaceutical compositions that contain a therapeutically effective amount of the claimed compound according to the invention. The present compound and pharmaceutically acceptable salts thereof are highly effective in inhibiting the activity of the glutaminyl cyclase enzyme, which is involved in particular in processes of post-translational modification of the above-mentioned cytokines.

## Claims

### Claim 1

A method for treating a disease or condition caused by the aberrant activity of fractalkine and monocyte chemoattractant proteins 1-4 (CCL2, CCL7, CCL8, CCL13), wherein the a disease or condition or symptom is selected from the group consisting of pneumonia, bronchitis, bronchiolitis, alveolitis, an autoimmune disease, pain syndrome, fever and an elevated temperature, in the body, comprising administering to said body an effective amount of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dose of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione or a pharmaceutically acceptable salt thereof is from 0.01 to 0.2 g for a patient per day.

### Claim 3 (depends on 2)

The method of claim 2, wherein the dose of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione or a pharmaceutically acceptable salt thereof is from 0.1 to 0.2 g for a patient per day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the autoimmune disease is psoriasis or rheumatoid arthritis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease or condition or symptom is selected from the group consisting of non-viral pneumonia, non-viral bronchitis, non-viral bronchiolitis, alveolitis, autoimmune disease, pain syndrome, fever, and an elevated temperature.